Litman Gregory Wealth Management’s Pacira BioSciences PCRX Stock Holding History

Litman Gregory Wealth Management’s Portfolio PCRX Stock Details PCRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q4	$19.4K	Buy	+750	New	+$17.8K	﹤0.01%	273

Other funds holding PCRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

DPCM

Doma Perpetual Capital Management Miami, Florida $431M AUM 13.21% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

State Street Boston, Massachusetts $3.38T AUM 44.17% 1-Year Est. Return

American Century Companies Kansas City, Missouri $226B AUM 44.75% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

Litman Gregory Wealth Management's PCRX Position: Q4 2025 in Review

Litman Gregory Wealth Management opened a new position in Pacira BioSciences (PCRX) in Q4 2025: 750 shares worth $19.4K. The stake represents ﹤0.01% of the portfolio and ranks #273 among its holdings.

260 funds tracked by Wall St. Rank hold PCRX as of Q4 2025.

Litman Gregory Wealth Management held 750 shares of Pacira BioSciences worth $19.4K as of Q4 2025.
Pacira BioSciences was a new Litman Gregory Wealth Management position in Q4 2025.
Pacira BioSciences made up ﹤0.01% of Litman Gregory Wealth Management's portfolio in Q4 2025, its #273 holding.
260 funds tracked by Wall St. Rank held Pacira BioSciences as of Q4 2025.

Based on Litman Gregory Wealth Management's 13F filing for Q4 2025, filed 12 Feb 2026.